Title |
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
|
---|---|
Published in |
Journal of Hematology & Oncology, March 2023
|
DOI | 10.1186/s13045-023-01406-8 |
Pubmed ID | |
Authors |
Qiusha Huang, Xiao-hui Zhang, Delong Liu |
Abstract |
Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 25% |
France | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Members of the public | 2 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 8 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 2 | 25% |
Unspecified | 1 | 13% |
Student > Master | 1 | 13% |
Student > Bachelor | 1 | 13% |
Unknown | 3 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 2 | 25% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 13% |
Unspecified | 1 | 13% |
Unknown | 4 | 50% |